Floatz logo

Buparlisib

Recurrent/Refractory Secondary Central Nervous System Lymphoma

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent/Refractory Secondary Central Nervous System Lymphoma cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Buparlisib is also rated in:

breast cancerDormant
B
Indicative ·
58 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
54 / 100
View asset →
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →